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ABSTRACT
The emergence of tumour recurrence and resistance limits the survival rate for most tumour-bearing
patients. Only, combination therapies targeting pathways involved in the induction and in the mainten-
ance of cancer growth and progression might potentially result in an enhanced therapeutic efficacy.
Herein, we provided a prospective combination treatment that includes suberoylanilide hydroxamic acid
(SAHA), a well-known inhibitor of histone deacetylases (HDACs), and SLC-0111, a novel inhibitor of car-
bonic anhydrase (CA) IX. We proved that HDAC inhibition with SAHA in combination with SLC-0111 affects
cell viability and colony forming capability to greater extent than either treatment alone of breast, colorec-
tal and melanoma cancer cells. At the molecular level, this therapeutic regimen resulted in a synergistically
increase of histone H4 and p53 acetylation in all tested cell lines. Overall, our findings showed that SAHA
and SLC-0111 can be regarded as very attractive combination providing a potential therapeutic strategy
against different cancer models.
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Introduction
Despite the sharp increase of therapeutic options, cancer remains
the second leading cause of death worldwide1,2. Indeed, although
selective drugs targeting oncogenic driver mutations are initially
highly effective, acquired resistance to chemo- and target-therapy
occurs and, often results in tumour relapse and low quality of
patient life3–6. Nonetheless, the rationale for most cancer thera-
peutic strategies is to target malignant cancer cells while largely
ignoring tumour microenvironment in which they are endowed7,8.
The fast proliferation of tumour cells, due to the accumulation of
genetic and epigenetic alterations, rapidly results in a limitation of
oxygen availability and ultimately hypoxia9,10. Hence, hypoxia trig-
gers several events such as metabolic reprogramming of tumour
cells, and modulation of tumour microenvironment (TME) that
results in the rearrangement of extracellular matrix and formation
of new faulty and leaky vessels, which may lead to metastasis11.
In order to survive in an oxygen deficient environment, tumour
cells reprogramme their metabolism to an anaerobic glycolysis
resulting in the intracellular accumulation of lactic and carbonic
acid12–16. To avoid the toxic intracellular acidification, tumour cells
potentiate the expression of extrusion mechanisms, including
monocarboxylate transporters and proton flux regulators, such as
vacuolar Hþ-ATPases, Naþ/Hþ exchanger, Naþ/HCO3 co-transporter
and carbonic anhydrase (CA) IX17–20. In particular, CA IX, catalysing
the reversible conversion of carbon dioxide to a proton and bicar-
bonate and thereby neutralising the acidic conditions, allows
tumours (i) to survive in a hostile environment with low oxygen-
ation and low pH, and hence (ii) to resist to chemo and
radiotherapy and (iii) to suppress anticancer immune responses.
Indeed, increased expression of CA IX has been shown in a wide
spectrum of tumour histo-types compared with normal tissues.
Since several clinical studies show a clear relationship between
high CA IX levels in tumours and a poor prognosis, CA IX is likely
an attractive target for cancer therapy21–25. Indeed, CA inhibitors
have been shown to elicit synergistic effects when used in com-
bination with other chemotherapeutic agents, thus represents a
well-suited agent to use alongside conventional therapy: this is
the so-called complementary therapy of cancer. Our earlier studies
showed that SLC-0111, a novel CA IX inhibitor, is able to synergize
with cytotoxic drugs such as Dacarbazine, Doxorubicine and 5-
Fluorouracil in melanoma, breast and colorectal cancer cell lines,
which express high levels of CA IX also in normoxia26.
Given the fact that the one of the most common epigenetic
alteration in tumour onset and progression is the overexpression
or the aberrant recruitment of histone deacetylases (HDACs) to
the promoter of tumour suppressor genes27–29, HDACs have been
considered as therapeutic targets for the treatment of cancer.
HDACs deacetylate the lysine residues on histones leading to the
inaccessibility of transcriptionally active regions of DNA. HDACs
are also responsible for removing the acetyl group from non-
histone proteins such as p53 and thus, interfering with several cel-
lular process such as DNA damage repair, protein stability and
DNA binding activity of transcriptional factors. According to the
Human Protein Atlas HDACs are expressed in a variety of
tumors30–35 and some HDAC isoforms such as HDAC2 was found
expressed in 100% of multiple tumors36. As a consequence,
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histone deacetylase inhibitors (HDACi) have emerged as important
agents for cancer treatment due to their multiple anti-cancer
effects, such as the ability to induce differentiation, cell cycle
arrest, apoptosis and inhibit angiogenesis37–41. However many
HDACi are very efficient in vitro, when given as monotherapy, but
may be toxic in vivo at therapeutic levels and their use is recom-
mended in patients who had failed or relapsed from standard
therapy. To date, suberoylanilide hydroxamic acid (SAHA), a
second generation HDAC inhibitor, has shown to arrest cell cycle
progression and promote cancer cell apoptosis in vitro on differ-
ent solid tumours while its use in clinical trials is limited for the
treatment of recurrent T-cell lymphoma42.
Currently, there is a great interest in developing combined
approaches aiming to create synergistic or additive effects and
thus, to improve the therapeutic index avoiding adaptative resist-
ance and toxic effects. Herein, we report the antiproliferative
effects of SAHA in combination with SLC-0111 on breast, colorec-
tal and melanoma cancer cells. We proved that HDAC inhibition in
combination with SLC-0111 affects either short-term and long-
term cell proliferation to greater extent than either treatment
alone causing a synergistic increase of H4 and p53 acetylation in
all tested cell lines. Our findings provided a new potential thera-
peutic strategy of SAHA and CA IX inhibition in different can-
cer models.
Materials and methods
Cell lines and culture conditions
In this study, we used A375M6, isolated in our laboratory from
lung metastasis of SCID bg/bg mice i.v. injected with A375 human
melanoma cell lines, obtained from American Type Culture
Collection (ATCC, Rockville, MD), human colorectal carcinoma cell
line HCT116, a kind gift of Dr. Matteo Lulli, Department of Clinical
and Experimental Biomedical Sciences, University of Florence and
human breast carcinoma MCF7 (from ATCC). Cells were supple-
mented with 10% foetal bovine serum (FBS, Euroclone, MI, Italy),
at 37 C in humidified atmosphere containing 90% air and 10%
CO2. Viability of the cells was determined by trypan blue exclusion
test. Cultures were periodically monitored for mycoplasma con-
tamination using Chen’s fluorochrome test. According to the
experiments, cells were treated with a CA IX inhibitor, SLC-0111,
developed in the laboratory of Prof. C.T. Supuran22 alone or in
combination with SAHA (from Sigma-Aldrich, Milan, Italy).
MTT assay
Cell viability was assessed using MTT (3–(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) tetrazolium reduction assay
(Sigma Aldrich, Milano). Cells were plated into 96-multiwell plates
in complete medium without red phenol. FC16 and SAHA were
added to the medium colture for 72 h. Then the MTT reagent was
added to the medium and plates were incubated at 37 C. After
2 h, MTT was removed and the blue MTT–formazan product was
solubilised with Dimethyl sulfoxide (DMSO) (Sigma Aldrich,
Milano). The absorbance of the formazan solution was read at
595 nm using the microplate reader (Bio-Rad).
Cell cycle analysis
Cell cycle distribution was analysed via the DNA content using the
PI staining method. Cells were centrifugated and stained with a
mixture of 50mg/mL PI (Sigma-Aldrich, St. Louis, MO, USA), 0.1%
trisodium citrate and 0.1% NP40 (or triton x-100) (Sigma-Aldrich,
St. Louis, MO, USA) in the dark at 4 C for 30min. The stained cells
were analysed via flow cytometry (BD-FACS Canto, BD Biosciences,
Franklin Lakes, NJ, USA) using red propidium-DNA fluorescence.
Plate colony forming assay
Approximately 100 cells/mL were seeded in fresh medium, and
incubated at 37 C. The following day cells were treated with
drugs and incubated at 37 C for two weeks, during which treat-
ment was repeated two times. After two weeks cells were washed
with PBS, fixed in cold methanol, and stained using a Diff Quik kit
(BD Biosciences). The stained colonies were photographed with a
digital camera and the number of colonies in each well
was counted.
Western blotting analysis
Cells were washed with ice cold PBS containing 1mM Na4VO3,
and lysed in cell RIPA lysis buffer (Merk Millipore, Vimodrone, MI,
Italy) containing sodium orthovanadate (Sigma-Aldrich) and prote-
ase inhibitor (Life Technologies, Monza, Italy). Aliquots of superna-
tants containing equal amounts of protein (30mg) in Laemmli
buffer were separated on BoltVR Bis-Tris Plus gels 4–12% precast
polyacrylamide gels (Life Technologies, Monza, Italy). Fractionated
proteins were transferred from the gel to a PVDF nitrocellulose
membrane using iBlot 2 system (Life Technologies, Monza, Italy).
Blots were stained with Ponceau red to ensure equal loading and
complete transfer of proteins, then they were blocked for 1 h, at
room temperature, with 5% milk in PBS 0.1% tween solution.
Subsequently, the membrane was probed at 4 C overnight with
the following primary antibodies; rabbit anti-PARP (Cell Signaling);
rabbit anti-acetylated Histon4 (Upstate), rabbit anti acetylated p53
(Upstate); while rabbit anti-GAPDH (cell Signaling) was used to
assess equal amount of protein loaded in each lane. Anti-Rabbit
IgG (whole molecule)–Peroxidase antibody (Sigma) has been used
as secondary antibodies; the ECL procedure was employed for
development.
Results
Dual HDAC and CA IX targeting reduces the growth of A375M6,
HCT116 and MCF7 cancer cells
We explored the anti-tumour activity of the histone deacetylase
(HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA) alone or
in combination with the CA IX inhibitor, SLC-0111, across panel of
cancer cell lines. The MTT cell proliferation assay was performed
to monitor the cell viability of A375-M6 melanoma, HCT116 colo-
rectal, MCF7 breast cancer cells treated for 72 h with increasing
doses of SAHA alone or in combination with a fixed dose of SLC-
0111, which was determined in a previous study26. As shown in
Figure 1(A) SAHA inhibited cell proliferation in a dose-dependent
manner in all cell lines whereas combination of SAHA and SLC-
0111 significantly enhanced the effectiveness of SAHA at the low-
est dose. Of note, HCT116 and MCF7 shared similar relative
sensitivity to these two inhibitors, while A375-M6 cells were less
responsive to SAHA. Similar differences across cell lines were also
observed using other cell proliferation assay such as cell cycle dis-
tribution. To characterise whether SAHA caused cells to arrest in a
specific cell cycle phase, A375M6, HCTC116 and MCF7 cells were
treated with the lowest tested dose of SAHA for 72 h. Cell cycle
distribution analysis in Figure 1(B) showed that SAHA alone and in
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combination with SLC-0111 increased the percentage of cells in
G2/M phase to about 20% in HCT116 and 10% in MCF7 cells
(Figure 1(B)), while no significant changes in cell cycle distribution
were observed for A375M6 cells. Moreover, FACS analysis revealed
that the combo treatment SAHA plus SLC-0111 was able to induce
an increase of the percentage of HCT116 cells in the sub-G1 phase
indicative of cell death, thus confirming the highest sensitivity of
this cell line to the drug combination.
Figure 1. SAHA- SLC-0111 efficacy on A375M6, HCT116 and MCF7. (A) Cell viability after 72 h treatment of SLC-0111 alone or in combination with three doses of
SAHA evaluated by MTT assay;  p  .05 refers to the co-treatment SLC-0111 þ SAHA respect to SAHA alone;  p  .05 refers to the co-treatment SLC-0111 þ
SAHA respect to SAHA and SLC-0111 alone. (B) Cell cycle distribution analysed by FACS; p  .05 refers to the co-treatment SLC-0111 þ SAHA respect to SLC-
0111 alone.
Figure 2. SAHA- SLC-0111 efficacy on the ability of A375M6, HCT116 and MCF7 to form colonies. (A) Colony Forming Units (CFU) assay of cells treated with SLC-0111
and/or SAHA;  p  .05 refers to the co-treatment SLC-0111 þ SAHA respect to SAHA and SLC-0111 alone.
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SAHA/SLC-0111 combined treatment completely restrained the
colony formation
We next performed a clonogenicity assay on A375M6, HCT116
and MCF7 cells treated either with SLC-0111, SAHA or the combin-
ation. Colonies were defined as cluster of 20 cells or more after
14 days. While colony formation was significantly reduced by SLC-
0111 or SAHA alone, combination treatment almost completely
abrogated the capability to form colonies (Figure 2(A)) of all three
cancer cell lines. It is worth noting the synergistic effect of the
two inhibitors on HCT116 cells and the strong sensitivity of MCF7
to the single agents alone.
Enhanced acetylation of p53 and H4 after dual HDAC and CA
IX inhibition
In order to illustrate the molecular basis of the inhibitor inter-
action, we performed western blot analysis for acetylated histone
H4 and acetylated not histone protein such as p53, which are tar-
get proteins of SAHA activity. We remarkably found a synergistic
increase of H4 and p53 acetylation on all three cancer cell lines
after the combo treatment (Figure 3(A)). To further investigate the
mechanism involved in apoptosis induction on HCT116 cells, the
cleavage of poly (ADP-ribose) polymerase (PARP) was studied
upon treatment with either single inhibitors alone or in combin-
ation. PARP cleavage by activated caspase-3 is known as an early
marker for apoptosis induction. Western blot images and analyses
Figure 3. Molecular effect after the treatment with SLC-0111 and/or SAHA. (A) (Left) Representative Western blot of PARP1, Acetyl H4, Acetyl p53 after the treatment
of A375M6 with SLC-0111 and/or SAHA. (Right) Densitometric quantification of PARP1, Acetyl H4, Acetyl p53 relative to GAPDH expression, expressed as a fold incre-
ment (%) compared to UT.  p  .05 refers to the co-treatment SLC-0111 þ SAHA respect to SAHA and SLC-0111 alone. (B) (Left) Representative Western blot of
Acetyl H4 and Acetyl p53 after the treatment of HCT116 with SLC-0111 and/or SAHA for 24 h and representative Western blot of PARP1 and cleaved PARP1 after the
treatment of HCT116 with SLC-0111 and/or SAHA for 24 h. (Right) Densitometric quantification of Acetyl H4, Acetyl p53, PARP1 and cleaved PARP1 relative to GAPDH
expression, expressed as a fold increment (%) compared to UT.  p  .05 refers to the co-treatment SLC-0111 þ SAHA respect to SAHA and SLC-0111 alone.
(C) (Left) Representative Western blot of PARP, Acetyl H4 and Acetyl p53 after the treatment of MCF7 with SLC-0111 and/or SAHA for 6h. (Right) Densitometric quanti-
fication of PARP1, Acetyl H4 and Acetyl p53 relative to GAPDH expression, expressed as a fold increment (%) compared to UT.  p  .05 refers to the co-treatment
SLC-0111 þ SAHA respect to SAHA and SLC-0111 alone.
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showed that cleaved PARP was observed after treating HCT116
cells with either SAHA or SLC-0111 alone, while was enhanced in
presence of both inhibitors. These data were consistent with the
increase of sub G1 population induced by the combo treatment
and measured by FACS analysis. No detectable cleaved fragments
were observed on A375M6 and MCF7 cells.
Discussion and conclusions
The combination of two or more drugs targeting different cancer
pathways is now being actively pursued43–46. This approach cre-
ates synergistic effects able to reduce the emergence of tumour
recurrence and resistance, since cancer cells are most likely incap-
able of adapting to the simultaneous effects of two therapeutic
agents47–51. However, a combination therapy does not exclude
side effects in treated patients, disclosing the need for a combin-
ation therapy made by standard chemotherapy and biological
drugs. In this study, we provide a prospective combination of
treatment that includes an inhibitor of histone deacetylases
(HDACs), as their dysregulation is associated with many forms of
cancers29–36, and an inhibitor of CA IX, as its overexpression in
various tumours is correlated with cancer progression and poor
survival17,52. We have previously reported that melanoma, breast
and colorectal cancer cell lines, express high levels of CA IX in
normoxia whereas the transiently and chronically exposure to
extracellular acidic microenvironment (pH 6.7 ± 0.1) induces CA IX
overexpression53. Moreover, we demonstrated that SLC-0111, a
novel CA IX inhibitor, is able to synergize with cytotoxic drugs
such as Dacarbazine, Doxorubicine and 5-Fluorouracil26.
In the past 20 years, histone deacetylase inhibitors (HDACi),
have emerged as promising chemotherapeutic agents in pre-clin-
ical and clinical trials. The specific appeal of HDACi for tumour
treatment is due to their ability to induce differentiation, cell cycle
arrest, apoptosis, autophagy and restrain angiogenesis. The spe-
cific function of HDACi is to inhibit the activity of histone deacety-
lases, enzymes that deacetylate the lysine residues on histone
molecules and as well as on non-histone proteins, thus removing
the transcriptional repression28,54. Trichostatin A was the first
HDACi tested in clinical trials while SAHA, a potent inhibitor of
HDAC1, HDAC2, HDAC3 and HDAC6, was the first FDA-approved
HDACi for the treatment of recurrent cutaneous T-cell lymph-
oma42. In preclinical setting, SAHA has been shown to inhibit
tumour growth, to induce cell cycle arrest, differentiation or apop-
tosis in a variety of transformed cell lines, including breast cancer
cells54,55. Depending on dose, time of treatment, and cell line,
SAHA can induce a G1 or G2/M cell cycle arrest. Furthermore, a
recent study unveiled that the tumour selective action of SAHA is
associated with compromised DNA repair mechanism, such as a
defective checkpoint kinase 1 (Chk1) in several cancer cells56,57.
Thus, the preferential efficacy of HDACi on cancer cells and their
capability to synergistically enhance the anti-tumour potential of
chemotherapeutic agents have prompted numerous preclinical
and clinical investigations.
In the current study, we found that the administration of CA IX
inhibitor potentiated the antitumor activity of SAHA in several
cancer lines. Notably, we discovered that the combination of
SLC-0111 (100 mM) and SAHA (1 mM) displayed significantly higher
effects on cell viability and colony forming capability, compared
to either agent alone for the treatment of melanoma, breast and
colorectal cancer. Moreover, according to FACS analysis we
observed, that cell cycle changes induced by single or combined
HDACi/CA IXi treatment depended on the cell line used. In par-
ticular, we were able to detect a distinctly enhanced apoptosis
only on colon cancer cells after the 24 h combined treatment. The
apoptotic effects were confirmed by the induction of
PARP cleavage.
At the molecular level we proved that the synergistic interac-
tions between the two inhibitors was associated to the enhanced
acetylation of H4 and p53, that is one of the first recognised and
important non-histone proteins targeted by HDACs. It has been
demonstrated that p53 regulates cell apoptosis and autophagy
among its multitude of other functions as the “gatekeeper” of the
cell. Since p53 acetylation is crucial for its transcription-independ-
ent pro-apoptotic functions, the higher p53 acetylation level in
HCT116 compared to the other cell lines might also explain why
single and combined treatments are effective in induc-
ing apoptosis.
Overall, our findings along with the results obtained in other
studies58 showed that the CA inhibitor with HDACi can be
regarded as a very attractive combination for the treatment of dif-
ferent types of tumours. In the current study, the combined treat-
ment beyond exerting anti-proliferative effects on several cancer
cell lines, has also the ability of inducing in vitro apoptosis of
colon cancer cells. Moreover, a highly effective synergism between
the two molecules might help in decreasing SAHA concentrations
at levels that might be less toxic, thus offering a new promise in
the combined pharmacological treatment of various tumour histo-
types, escaping side effects in the patients.
Although some hydroxamates have been reported to possess
significant CA inhibitory properties,59–61 SAHA is not among these
derivatives. Indeed, against isoforms CA IX and XII SAHA showed
no inhibition up to 50 mM (unpublished results from the authors’
laboratories). Thus, the synergy reported in the present work is
indeed due to the concomitant inhibition of the tumour associ-
ated CA isoforms (e.g. CA IX) by the sulphonamide derivative SLC-
0111, and of the HDAC isoforms involved in tumorigenesis
by SAHA.
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